Vaccines Research Unit, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, FISABIO-Public Health, Avda. Cataluña, 21, 46020, Valencia, Spain.
Universidad Católica de Valencia San Vicente Mártir, Carrer de Quevedo, 2, 46001, València, Spain.
BMC Infect Dis. 2020 Nov 30;20(1):905. doi: 10.1186/s12879-020-05648-6.
Estimate the incidence of herpes zoster (HZ), its complications and healthcare utilization rates in adults (≥ 18-years-old) with a wide range of immunocompromised (IC) conditions compared to IC-free cohort.
A population-based retrospective study using the Valencia healthcare Integrated Databases (VID) (2009-2014). HZ and IC were defined using ICD-9 codes in primary care (PC) and hospitalization registers. Incidence rates (IR), risk of HZ, HZ-recurrence, HZ-complications and healthcare utilization rates were estimated in the IC-cohort compared to IC-free.
The study population consisted of 4,382,590 subjects, of which 578,873 were IC (13%). IR (in 1000 persons-year) of HZ overall, in IC and in IC-free cohort was 5.02, 9.15 and 4.65, respectively. IR of HZ increased with age in both cohorts and it was higher for all IC conditions studied, reaching up to twelvefold in subjects with stem cell transplantation. IC subjects had 51% higher risk of developing HZ, 25% higher HZ-recurrence and the risk of HZ-complications was 2.37 times higher than in IC-free. HZ-related healthcare utilization was higher in the IC-cohort than in IC-free (number of hospitalizations 2.93 times greater, hospital stays 12% longer, 66% more HZ-specialist visits, 2% more PC visits, sick leaves 18% longer and 20% higher antiviral dispensation).
Patients suffering from all the IC conditions studied are at higher risk of developing HZ, HZ-recurrence and post-herpetic complications, which implies a substantial morbidity and a high consumption of resources. These results should be considered for vaccine policy implementation.
本研究旨在比较广泛免疫抑制(IC)人群与非 IC 人群中,不同程度免疫抑制成人(≥18 岁)带状疱疹(HZ)的发病率、并发症及卫生保健资源利用情况。
本研究为基于人群的回顾性研究,采用 Valencia 医疗综合数据库(VID)(2009-2014 年)。初级保健(PC)和住院记录中使用 ICD-9 编码来定义 HZ 和 IC。与非 IC 人群相比,IC 人群的 HZ 发病率(IR)、HZ 风险、HZ 复发、HZ 并发症和卫生保健资源利用情况。
研究人群包括 4382590 例患者,其中 578873 例为 IC(13%)。总体而言,IC 人群和非 IC 人群的 HZ IR(每 1000 人年)分别为 5.02、9.15 和 4.65。在两个队列中,HZ 的发病率均随年龄增长而增加,所有研究的 IC 疾病的发病率均较高,在接受干细胞移植的患者中,发病率可高达 12 倍。IC 患者发生 HZ 的风险增加 51%,HZ 复发风险增加 25%,HZ 并发症风险增加 2.37 倍。与非 IC 人群相比,IC 人群的 HZ 相关卫生保健资源利用率更高(住院人数增加 2.93 倍,住院时间延长 12%,HZ 专科就诊次数增加 66%,PC 就诊次数增加 2%,病假延长 18%,抗病毒药物使用增加 20%)。
患有所有研究的 IC 疾病的患者发生 HZ、HZ 复发和疱疹后并发症的风险更高,这意味着发病率较高,资源消耗较大。这些结果应在疫苗政策实施中加以考虑。